Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Befiradol - Neurolixis

Drug Profile

Befiradol - Neurolixis

Alternative Names: F-13,640; NLX 112

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pierre Fabre
  • Developer Neurolixis; Pierre Fabre
  • Class Antiparkinsonians; Non-opioid analgesics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Phase II Diabetic neuropathies
  • Clinical Phase Unknown Drug-induced dyskinesia
  • Discontinued Cancer pain; Neuropathic pain

Most Recent Events

  • 22 Jul 2019 Neurolixis has world patent protection for Befiradol
  • 14 Mar 2019 Neurolixis plans a phase II trial for Drug-induced dyskinesia in patients with Parkinson’s disease in USA
  • 12 Mar 2019 US FDA approves IND application for befiradol in Drug-induced dyskinesia in Parkinson's disease patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top